Syncona Limited has issued its quarterly update, reporting an increase in net assets and a positive NAV per share return. The company's life science portfolio also saw significant growth. Read more for details. #Syncona #quarterlyupdate #lifescienceinvestment
Syncona's portfolio company, Freeline, releases positive data on gene therapy for Gaucher disease directorstalkinterviews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from directorstalkinterviews.com Daily Mail and Mail on Sunday newspapers.
Syncona to Acquire Freeline Therapeutics – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.